Opus Genetics (IRD) Current Leases (2019 - 2020)
Opus Genetics (IRD) posted quarterly Current Leases of $100397.0 for Q3 2020, down 25.66% year-over-year from $135052.0 in Q4 2019, and down 26.29% quarter-over-quarter from $136197.0 in Q2 2020.
Powered by 
Analysis
Opus Genetics (IRD) Current Leases (2019 - 2020) Analysis & Trends
Opus Genetics (IRD) has reported Current Leases for 2 consecutive years, with $100397.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Current Leases fell 25.66% year-over-year to $100397.0; the TTM figure through Sep 2020 stood at $100397.0 (down 25.66% YoY), while the FY2019 annual figure was $139765.0, changed N/A from the prior year.
- Current Leases eased to $100397.0 in Q3 2020 per IRD's latest filing, from $136197.0 in the prior quarter.
- Across five years, Current Leases topped out at $144610.0 in Q1 2020 and bottomed at $100397.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 100,397.00 |
| Jun 30, 2020 | 136,197.00 |
| Mar 31, 2020 | 144,610.00 |
| Dec 31, 2019 | 139,765.00 |
| Sep 30, 2019 | 135,052.00 |
| Jun 30, 2019 | 130,466.00 |
| Mar 31, 2019 | 113,531.00 |